CL2016003295A1 - Dosificación intermitente de un inhibidor de mdm2. - Google Patents
Dosificación intermitente de un inhibidor de mdm2.Info
- Publication number
- CL2016003295A1 CL2016003295A1 CL2016003295A CL2016003295A CL2016003295A1 CL 2016003295 A1 CL2016003295 A1 CL 2016003295A1 CL 2016003295 A CL2016003295 A CL 2016003295A CL 2016003295 A CL2016003295 A CL 2016003295A CL 2016003295 A1 CL2016003295 A1 CL 2016003295A1
- Authority
- CL
- Chile
- Prior art keywords
- mdm2 inhibitor
- mdm2i
- mdm2
- treatment
- intermittent dosing
- Prior art date
Links
- 239000012819 MDM2-Inhibitor Substances 0.000 title abstract 4
- 229940083338 MDM2 inhibitor Drugs 0.000 title abstract 3
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>LA PRESENTE DESCRIPCIÓN SE REFIERE A INHIBIDORES DE MDM2 PARA SU USO EN ESQUEMAS DE DOSIFICACIÓN ESPECÍFICOS. SE ENCONTRÓ QUE SI SE UTILIZA UNA DOSIS LO SUFICIENTEMENTE POTENTE O, EN ALTERNATIVA, SUFICIENTEMENTE ALTA DE UN INHIBIDOR DE MDM2, PUEDE CAUSAR UN EFECTO ANTINEOPLÁSICO DESENCADENANDO UN MECANISMO ANTIPROLIFERATIVO MUCHO MÁS DURADERO EN LAS CÉLULAS. EL EFECTO DE LARGA DURACIÓN SE PUEDE MANTENER DURANTE VARIAS SEMANAS DESPUÉS DE UNA DOSIS ÚNICA, LO QUE ELIMINA LA NECESIDAD DE TRATAMIENTO DIARIO Y PERMITE ADMINISTRAR EL MDM2I DE FORMA INTERMITENTE. UN TRATAMIENTO CON EL PROGRAMA DE DOSIFICACIÓN INTERMITENTE DE UN INHIBIDOR DE MDM2 SE PUEDE COMBINAR CON UN TRATAMIENTO DIARIO DEL MDM2I O CON OTRO INGREDIENTE FARMACÉUTICAMENTE ACEPTABLE.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462017406P | 2014-06-26 | 2014-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016003295A1 true CL2016003295A1 (es) | 2017-07-28 |
Family
ID=53510950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016003295A CL2016003295A1 (es) | 2014-06-26 | 2016-12-22 | Dosificación intermitente de un inhibidor de mdm2. |
Country Status (18)
Country | Link |
---|---|
US (5) | US20170196866A1 (es) |
EP (1) | EP3160463B1 (es) |
JP (1) | JP6728072B2 (es) |
KR (2) | KR20220151027A (es) |
CN (2) | CN106456635A (es) |
AU (1) | AU2015278765B2 (es) |
BR (1) | BR112016029750A2 (es) |
CA (1) | CA2953079C (es) |
CL (1) | CL2016003295A1 (es) |
ES (1) | ES2856210T3 (es) |
IL (1) | IL249138B (es) |
MX (1) | MX2016017075A (es) |
PH (1) | PH12016502556A1 (es) |
RU (1) | RU2695228C2 (es) |
SG (1) | SG11201609853VA (es) |
TN (1) | TN2016000522A1 (es) |
TW (1) | TW201613576A (es) |
WO (1) | WO2015198266A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2682174C (en) | 2007-03-28 | 2021-04-06 | President And Fellows Of Harvard College | Stitched polypeptides |
WO2012021876A2 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
BR112017005736A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e formulações dos mesmos |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
ES2880149T3 (es) | 2016-11-15 | 2021-11-23 | Novartis Ag | Dosis y régimen para inhibidores de la interacción HDM2-p53 |
RU2753527C2 (ru) * | 2017-03-31 | 2021-08-17 | Новартис Аг | ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ |
US11639355B2 (en) | 2018-03-12 | 2023-05-02 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors |
EP3768717A1 (en) | 2018-03-20 | 2021-01-27 | Novartis AG | Pharmaceutical combinations |
IL278345B2 (en) * | 2018-04-30 | 2024-05-01 | Kartos Therapeutics Inc | Cancer treatment methods |
WO2020128892A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Extended low dose regimens for mdm2 inhibitors |
JP2022547311A (ja) | 2019-09-16 | 2022-11-11 | ノバルティス アーゲー | 骨髄線維症の治療のためのmdm2阻害剤の使用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
US20030139373A1 (en) | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
CA2598690C (en) | 2005-02-22 | 2011-11-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
CN102770182B (zh) * | 2009-12-22 | 2014-10-29 | 诺华股份有限公司 | 被取代的异喹啉酮类和喹唑酮类 |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
EP2361667B1 (en) | 2010-02-25 | 2015-04-01 | Alstom Technology Ltd | A wet scrubber and a method of cleaning a process gas |
NZ611866A (en) * | 2010-11-12 | 2015-04-24 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
CN103261229A (zh) * | 2010-12-16 | 2013-08-21 | 罗切格利卡特公司 | 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法 |
EA028780B1 (ru) | 2011-08-11 | 2017-12-29 | Эстетра С.П.Р.Л. | Применение эстетрола в качестве экстренного контрацептива |
US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
HUE045880T2 (hu) * | 2012-07-31 | 2020-01-28 | Novartis Ag | A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
DK3077004T3 (da) | 2013-12-05 | 2020-04-27 | Hoffmann La Roche | Hidtil ukendt kombinationsbehandling af akut myeloid leukæmi (AML) |
JP6675313B2 (ja) | 2013-12-23 | 2020-04-01 | ノバルティス アーゲー | 組合せ医薬 |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
JP2018508569A (ja) | 2015-02-06 | 2018-03-29 | ユニティ バイオテクノロジー インコーポレイテッド | 老化関連状態の治療における化合物および使用 |
EP3284466A4 (en) | 2015-04-13 | 2018-12-05 | Daiichi Sankyo Company, Limited | Treatment method combining mdm2 inhibitor and btk inhibitor |
TWI750129B (zh) | 2015-08-03 | 2021-12-21 | 瑞士商諾華公司 | 作為血液學毒性生物標記之gdf-15 |
US20190060309A1 (en) | 2015-08-28 | 2019-02-28 | Novartis Ag | Mdm2 inhibitors and combinations thereof |
ES2880149T3 (es) | 2016-11-15 | 2021-11-23 | Novartis Ag | Dosis y régimen para inhibidores de la interacción HDM2-p53 |
HUE057029T2 (hu) | 2016-11-22 | 2022-04-28 | Novartis Ag | Kémiai eljárás imidazopirrolidinon-származékok és ezek köztitermékei elõállítására |
WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
RU2753527C2 (ru) | 2017-03-31 | 2021-08-17 | Новартис Аг | ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ |
WO2019073435A1 (en) | 2017-10-12 | 2019-04-18 | Novartis Ag | COMBINATIONS OF MDM2 INHIBITORS WITH ERK INHIBITORS TO TREAT CANCERS |
EP3768717A1 (en) | 2018-03-20 | 2021-01-27 | Novartis AG | Pharmaceutical combinations |
JP2022505884A (ja) | 2018-10-30 | 2022-01-14 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | p53WT腫瘍の処置の方法 |
WO2020128892A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Extended low dose regimens for mdm2 inhibitors |
WO2020202052A1 (en) | 2019-04-04 | 2020-10-08 | Novartis Ag | Siremadlin succinate |
-
2015
- 2015-06-24 TW TW104120384A patent/TW201613576A/zh unknown
- 2015-06-25 CN CN201580034558.4A patent/CN106456635A/zh not_active Withdrawn
- 2015-06-25 US US15/321,042 patent/US20170196866A1/en not_active Abandoned
- 2015-06-25 CA CA2953079A patent/CA2953079C/en active Active
- 2015-06-25 TN TN2016000522A patent/TN2016000522A1/en unknown
- 2015-06-25 KR KR1020227037821A patent/KR20220151027A/ko not_active IP Right Cessation
- 2015-06-25 SG SG11201609853VA patent/SG11201609853VA/en unknown
- 2015-06-25 AU AU2015278765A patent/AU2015278765B2/en active Active
- 2015-06-25 WO PCT/IB2015/054792 patent/WO2015198266A1/en active Application Filing
- 2015-06-25 MX MX2016017075A patent/MX2016017075A/es unknown
- 2015-06-25 ES ES15733926T patent/ES2856210T3/es active Active
- 2015-06-25 JP JP2016574274A patent/JP6728072B2/ja active Active
- 2015-06-25 KR KR1020167035797A patent/KR102462177B1/ko active IP Right Grant
- 2015-06-25 CN CN202211129314.2A patent/CN115569197A/zh active Pending
- 2015-06-25 RU RU2017102319A patent/RU2695228C2/ru active
- 2015-06-25 EP EP15733926.8A patent/EP3160463B1/en active Active
- 2015-06-25 BR BR112016029750A patent/BR112016029750A2/pt not_active Application Discontinuation
-
2016
- 2016-11-22 IL IL249138A patent/IL249138B/en active IP Right Grant
- 2016-12-20 PH PH12016502556A patent/PH12016502556A1/en unknown
- 2016-12-22 CL CL2016003295A patent/CL2016003295A1/es unknown
-
2017
- 2017-12-21 US US15/849,770 patent/US20180110779A1/en not_active Abandoned
-
2018
- 2018-12-17 US US16/221,650 patent/US20190209561A1/en not_active Abandoned
-
2020
- 2020-06-11 US US16/898,886 patent/US11419870B2/en active Active
-
2022
- 2022-07-25 US US17/814,599 patent/US20230092181A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016003295A1 (es) | Dosificación intermitente de un inhibidor de mdm2. | |
CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CO2017012268A2 (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b | |
CR20160006A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
NI201600115A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
CL2018001705A1 (es) | Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. | |
UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
PE20151778A1 (es) | Formulacion combinada de dos compuestos antivirales | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
UY34993A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2018001199A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
EA202092456A3 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
CL2017001001A1 (es) | Derivados de carbazaol | |
CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
NI201800071A (es) | Compuestos de isoindol | |
TR201901348T4 (tr) | Metap-2 inhibitörleri olarak pirolidinon türevleri. | |
CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
CL2016000027A1 (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán. |